The Number 1 Medical Device Stock to Buy Right Now



Breakthrough Technology Now Allows Transdermal Delivery of Insulin
Potentially improving the lives of millions of diabetics worldwide who currently have to suffer by injecting themselves up to 10 times a day.
Possibly the drug delivery discovery of the decade - applicable to hundreds of "large molecule" drugs currently only available to people via injection or orally.  
"The company behind this discovery, Dermisonics, could return a 1,000% gain to early-stage investors who get in now."
Dermisonics, Inc. (OTC Bulletin Board: DMSI) is a - presently - little known company that has made some incredible breakthrough discoveries in drug delivery. Most drugs have to be ingested orally or injected. But, if you take a pill, the drug could be destroyed by stomach acids and not be effective, or as often happens, the drug could produce toxins in the body and affect the liver. However, when a drug is absorbed through the skin in a transdermal patch the stomach and liver are not affected and the patient gets the full dose, without any unforeseen side effects.

So why don't more drugs come in patch form???
The last twenty years have seen incredible, miraculous discoveries in drug therapies by pharmaceutical companies that now rake in BILLIONS of dollars - every year. Most of these drugs are derived from protein - peptide molecules. But, these molecules are just too big to make it through the skin -- unassisted that is.

So why not figure out a way to get drugs through the skin with a device?
Well, Dermisonics now has and it's a huge breakthrough discovery. The Company figured out something no one had thought of before - hook up a regular transdermal patch to a miniature ultrasonic device that opens the pores of the skin and pushes the drug through the layers into the tissue where it acts just the way an injection would.

And it works. The Company took insulin and tested the patch (called the U-Strip) on real live healthy humans and proved in a Human Pilot Trial that they can deliver insulin.


Of course, Dermisonics filed patents to make sure their idea was protected and the US Patent Office has just told the Company that they are allowing the first of their patents - a patent which covers ALL the major technology invented by Dermisonics.
Alexander Holtermann, financial journalist and editor of Bull-and-Bear.tv, on:





Dear reader - in today's issue let's talk about my pick of the month:

Dermisonics Inc., DMSI
The American Diabetes Association estimates that there were 145 million diabetics worldwide last year. The Center for Disease Control reports that diabetes In the US has grown by 61% since 1991 and that there are 7 million undiagnosed cases.

The annual market for diabetes therapies in the US alone exceeds 6 BILLION dollars.

Now what would happen if Dermisonics only captured a TINY ¼ of 1% of the domestic US market of 17 million patients—let’s just say 42, 500 users of the system?

Well, first it would realize $53 million in sales of the ultrasonic transducer – that’s like selling the razor. Then follow the razor blades. The patient uses a new patch every single day that costs $2.50 per day translating into $38 million of recurring revenue every single year – even better it's all covered by insurance and cheaper than the competition – Minimed’s $4,000 a unit invasive insulin pump.

Want to talk about real life numbers. Well, on May 30, 2001, Minimed was bought out by Medtronic for $3.7 BILLION on revenue of $256 million – 14 TIMES REVENUE!

Plus Dermisonics' technology is easier to use than Mimimed’s Pump, has none of the problems associated with having to open ports in the patient’s stomach and is much less bulky and inconvenient. Yet there are over 300,000 pump users worldwide today.

Based on Dermisonics' estimate of 42,500 users, a fraction of a fraction of the potential world market, Dermisonics would have recurring annual revenue of $38 million not to mention the fact that the transducer has to be replaced every 2 years. So, that means at least $100 million a year in sales.


Forget about valuations of 14 times sales, if Dermisonics trades at just 4 times sales, that means the stock goes from around $1.00 where it is today to more than $10.00 per share. And that’s with ONLY ONE QUARTER OF ONE PERCENT OF ONLY THE US MARKET AND FOR ONLY ONE PRODUCT LINE!

Now you know why DMSI could easily go to $10 a share!

Sincerely,


P.S. Click Here to See Dermisonics featured on CNBC!
http://www.bull-and-bear.tv  
COMPANY:
Dermisonics Inc.  
Stock Symbol:  
OTCBB: DMSI  
Recommendation:
Buy DMSI today up to $2.50

Since this is a highly speculative trade, limit your Dermisonics position to a small percentage of your overall portfolio.





THIS IS A GIGANTIC MARKET OPPORTUNITY

Not only are there millions of TYPE I (Juvenile Onset) diabetics out there suffering with daily insulin injections, there are over 150 million TYPE II Diabetics (a global PANDEMIC caused by junk food and the couch potato lifestyle) WHO WON'T TAKE INSULIN because they don't want to inject it. These Type II diabetics take all sorts of other pills to try to control their blood sugar. Some end up disabled, blind or amputees because of the ravages of the disease.

However, imagine how easy it would be just to stick on a patch with insulin connected to a miniature device the size of a credit card and dial in the right dose at the right time. It:

IS NON-INVASIVE
IS EASY TO USE
CONTROLS AND TIMES THE DOSAGE

Order your free Investor package here!



AND IT GETS MUCH BETTER YET BECAUSE ALL THOSE BIG DRUG COMPANIES - PRESENTLY RAKING IN BILLIONS OF DOLLARS EVERY YEAR FROM THEIR PATENTS - ARE DESPERATELY LOOKING FOR AN ALTERNATE WAY TO DELIVER THEIR DRUGS SO AS TO EXTEND THE LIVES OF THEIR OWN PATENTS
Remember Claritin™, a heavily advertised allergy drug? Well suddenly Claritin™ ads disappeared and time released Clarinex™ ads were all over TV. That's because Claritin™ went off patent and then had price competition from generics, so the company that made it just started marketing time release Clarinex™.

__________________________________________________________________________________

DERMISONICS ALREADY HAS IDENTIFIED AT LEAST 175 DRUGS THAT COULD BE DELIVERED USING IT'S OWN PATENTED U-STRIP TECHNOLOGY

Many of these are coming of patent and are blockbuster sellers. Do you think drug companies like Pfizer, Schering, Eli-Lilly, Sanofi-Aventis or GSK might be looking for a partner to help them extend patent life on drugs and protect billions in revenue in the worlds MOST PROFITABLE industry?

This really has to be one of the best buys of the year, if not the decade, because in addition to all the above, there is yet an:

EVEN BIGGER OPPORTUNITY OUTSIDE THE MEDICAL MARKET
A lot of people have seen the Sonicare ultrasonic toothbrush that has sold in the millions. What about an ultrasonic "wand" a handheld device to make all those billions of dollars of face creams and skin nutrients work much better? Think of the impact. Suddenly, that wrinkle cream really works because it doesn't just stay on the outer layer of the skin clogging up pores, but really penetrates. Dermisonics is working on this also, as well as designing its next round of human tests for the U-Strip.

Just go to the Dermisonics website: http://www.dermisonics.com for more exciting info.
__________________________________________________________________________________

No wonder that noted highly-conservative German research analyst Dr. Georg Hochwimmer of General Research GmbH rates Dermisonics a "Speculative BUY with tremendous upside potential for investors prepared to take risks."

AND THOSE GAINS ARE JUST FOR "NORMAL" COMPANIES SO

BUY DERMISONICS (DMSI) NOW
And now is the time to add this hot medical device stock to your portfolio.

Reason: The Company is in the early stages of R&D, so you and I are getting in on the ground floor - or close to it. Plus the stock is at its lowest ever - a low risk entry point.

Right now, Dermisonics researchers know that they can deliver a host of drugs transdermally and solve a multitude of problems for big pharmaceutical companies.

Once they move ahead with the next set of pilot trials or form an alliance with a big company the share price could easily skyrocket. Ten fold? Twenty fold? Possibly even more, because the potential here is nothing short of HUGE.

My recommendation: Buy Dermisonics today at the market price. Since this is a highly speculative trade, though, please do limit your position here to a small percentage of your overall portfolio.


Company Address:
BB Investment
3181 Constitution Drive
Belmopan
Belize, Central America



__________________________________________________________________________________
IMPORTANT NOTICE AND DISCLAIMER: This featured company sponsored advertising issue of Bull-and-Bear is presented by BB Investment, the private owner and publisher of Bull-and-Bear. Bull-and-Bear and BB Investment shall hereinafter be collectively referred to as Bull-and-Bear.

Bull-and-Bear does not purport to provide an analysis of any company's financial position, operations or prospects. This document is not to be construed as a recommendation by Bull-and-Bear or as an offer to buy or sell any security. Bull-and-Bear presents information in this report believed to be reliable, but its accuracy cannot be guaranteed by Bull-and-Bear. Dermisoncs' financial position and all information relating to the operations of Dermisonics should be verified with the company. Investing in securities is speculative and carries risk. You can lose all or part of your investment. It is recommended that any investment in any security should be made only after consulting with your investment advisor and only after reviewing the prospectus and/or financial statements of the target company. Information about publicly listed companies and other investor resources can be found at the Securities & Exchange Commission website http://www.sec.gov.
Bull-and-Bear's objective is to give the investor the necessary knowledge and information with which to make rational and profitable investment decisions. Bull-and-Bear received no monetary compensation with respect to the writing of this special report. Dermisonics, the company featured in this issue, appears as paid advertising, subsidized by BX Inc., a non-controlling shareholder of Dermisonics, to provide public and investor awareness for Dermisonics. Neither BX Inc., its employees and affiliates nor Bull-and-Bear are investment advisors and are not affiliated with each other, either directly or indirectly. Many states have established rules requiring the approval of a security by a state security administrator. Check with http://www.nasaa.org or call your state security administrator to determine whether a particular security is licensed for sale in your state. Many companies have information filed with state securities regulators and many will supply investors with additional information upon request.

The information contained herein contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934, including statements regarding expected continual growth of the featured company. In accordance with safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the statements contained herein that look forward in time, which include other than historical information, involve risks and uncertainties that may affect actual results of operations. Factors that could cause actual results to differ materially include, but are not limited to, adverse economic conditions, intense competition, lack of meaningful research results, inadequate capital, termination of contracts or agreements, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other specific risks detailed in Dermisonics' filings with the Securities and Exchange Commission on Form 10-KSB and 10-QSB. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should or might occur.